US Stock MarketDetailed Quotes

GUTS Fractyl Health

Watchlist

4.060
+0.070+1.75%

Close Jul 23 16:00 ET

3.950
-0.110-2.71%

Post 18:12 ET

194.46MMarket Cap1.85P/E (TTM)

Fractyl Health Stock Forum

Trytosaveabit

May 20 05:49

Update

$Fractyl Health(GUTS.US)$ Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024. VIA GLOBENEWSWIRE Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42%

Trytosaveabit

May 13 17:14

Looks way more impressive than it is! Hehehe. But who knows, it is a great increase.

$Fractyl Health(GUTS.US)$ Fractyl Health (NASDAQ:GUTS) reported quarterly losses of $(0.17) per share. This is a 97.84 percent increase over losses of $(7.87) per share from the same period last year. The company reported $33.000 thousand in sales this quarter. This is a 560.00 percent increase over sales of $5.000 thousand the same period last year.

Stock Region

Apr 2 06:50

Health Company Receives FDA Approval For Obesity Drug Study

A Revolutionary Step in Obesity Management: The Approval of Fractyl Health's Revita® Remain-1 Study.
In a groundbreaking development for the field of obesity management, Fractyl Health has received FDA Investigational Device Exemption (IDE) approval for its pivotal Revita® Remain-1 study. This marks a significant milestone in providing durable weight maintenance solutions for patients after the discontinuation of GLP-1 based drugs. With ...

Trytosaveabit

Apr 1 06:45

How s*itty of a trick! Hehehe

$Fractyl Health(GUTS.US)$ No longer looking for reversal! They release FDA news to get the PI! Then they release the big ole earnings loss! Hehehe!

Trytosaveabit

Apr 1 05:17

Looking for reversal

$Fractyl Health(GUTS.US)$ Fractyl Health Receives FDA IDE Approval for the Revita Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
Globe Newswire 1-Apr-2024 6:00 AM